Precision treatment for osteosarcoma based on immune markers
Part of Cancer clinical trials.
This trial studies the immune environment of osteosarcoma tumors to find more personalized treatments. It may help researchers understand why some treatments work better for certain patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with or are strongly suspected of having osteosarcoma (a type of bone cancer).
- You have a tumor that can be surgically removed or monitored.
- You are scheduled for surgery and are able to provide enough tumor tissue for testing.
- Your medical records are complete and available.
- You are willing to be followed up after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a lab-grown mini tumor (organoid) from your biopsy to test which drugs might work best for your osteosarcoma. It aims to personalize your treatment based on how your specific cancer cells respond.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial focuses on improving how osteosarcoma care is coordinated and delivered, using collaboration between clinicians. It may help by helping teams make more consistent treatment decisions for people newly diagnosed.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.